Article Contents ::
- 1 Details About Generic Salt :: Alitreti
- 2 Main Medicine Class:: Topical,endogenous retinoid
- 3 (al-ih-TREH-tih-NO-in) Panretin Class: Topical/endogenous retinoid
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Alitreti
Main Medicine Class:: Topical,endogenous retinoid
(al-ih-TREH-tih-NO-in)
Panretin
Class: Topical/endogenous retinoid
Drugs Class ::
Action Regulates genes that control cellular differentiation and proliferation of healthy and neoplastic cells by binding to and activating intracellular retinoid receptor subtypes; in vitro inhibition of growth of Kaposi’s sarcoma (KS) cells.
Indications for Drugs ::
Indications Treatment of cutaneous lesions in patients with AIDS-related KS.
Drug Dose ::
Route/Dosage
ADULTS: Topical Initially apply bid to cutaneous lesions, gradually increasing to tid or bid, according to individual-lesion tolerance. Apply sufficient gel to generously coat lesion.
Contraindication ::
Contraindications Standard considerations.
Drug Precautions ::
Precautions
Pregnancy: Category D. Lactation: Unknown. Children: Safety and efficacy not established. Elderly Patients: Safety and efficacy not established. Photosensitivity: Although not reported, in vitro data indicate a weak potential.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
DERM: Rash; erythema; scaling; irritation; redness; dermatitis; pain; burning; pruritus; itching; exfoliative dermatitis; flaking; peeling; desquamation; excoriation; cracking skin; scabbing; crusting; drainage; eschar; fissure; oozing; paresthesia; stinging; tingling; edema; swelling; inflammation.
Drug Mode of Action ::
Action Regulates genes that control cellular differentiation and proliferation of healthy and neoplastic cells by binding to and activating intracellular retinoid receptor subtypes; in vitro inhibition of growth of Kaposi’s sarcoma (KS) cells.
Drug Interactions ::
Interactions
N, N-diethyl-m-toluamide (DEET): DEET toxicity may be increased.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Monitor for signs of hypersensitivity and adverse reactions (eg, rash, pain, pruritus, exfoliative dermatitis, paresthesia, edema, swelling), which usually occur at the site of application.
- Discontinue use if signs of hypersensitivity are present and notify primary health care provider.
- Do not administer if systemic or other anti-KS therapy if required.
- Monitor for potential dermal toxicity, which usually begins as mild erythema and increases with continued application leading to intense erythema, edema, and vesiculation.
- Assess the patient for symptoms of systemic signs and symptoms of KS.
- If < 10 new KS lesions in the prior month or symptoms of lymphedema, pulmonary KS, or visceral involvement are present, do not administer and report findings to primary care provider.
Drug Storage/Management ::
Administration/Storage
- Store tubes at room temperature (25°C; 77°F) with excursions permitted to 15° to 30°C (59° to 86°F)).
- Apply as directed with sufficient gel to cover the lesions. Allow to dry 3 to 5 min before covering with clothing.
- Do not cover with occlusive dressings.
- Do not apply to surrounding skin, as unaffected skin may become irritated.
- Do not apply on or near mucosal membranes
Drug Notes ::
Patient/Family Education
- Teach patient that alitretinoin is for topical use only, and give instructions for correct application.
- Advise patient that the response to treatment is not immediate, but may require from ³ 2 to 14 wks for response.
- Discontinue medicine immediately if signs of hypersensitivity are present and notify primary health care provider.
- Warn patient not to use alitretinoin concurrently with insect repellent products that contain DEET, as the combination could lead to an increased risk of DEET toxicity.
- Advise patient of the photosensitivity potential, and to avoid exposure of treated areas to direct sunlight.
- Advise patient to avoid exposure of treated areas to sunlight or sunlamp.
- Warn women with childbearing potential to avoid becoming pregnant, and apprise them of the potential hazard to the fetus.
- Nursing mothers should discontinue nursing prior to using the drug.